期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 62, 期 17, 页码 8028-8052出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b00723
关键词
-
资金
- Lundbeck Foundation [R190-2014-3710]
- Drug Research Academy/Lundbeck Foundation
- China Scholarship Council [2017062200]
- A.P. Moller Foundation for the Advancement of Medical Science [14-28]
- Horsley Foundation [203866 MIA]
- Augustinus Foundation [14-1571, 16-2677]
- Danish Research Council for Independent Research I Nature and Universe [10-085264]
Inhibiting the protein-protein interaction (PPI) between the transcription factor Nrf2 and its repressor protein Keap1 has emerged as a promising strategy to target oxidative stress in diseases, including central nervous system (CNS) disorders. Numerous non-covalent small-molecule Keap1-Nrf2 PPI inhibitors have been reported to date, but many feature suboptimal physicochemical properties for permeating the blood brain barrier, while others contain problematic structural moieties. Here, we present the first side-by-side assessment of all reported Keap1-Nrf2 PPI inhibitor classes using fluorescence polarization, thermal shift assay, and surface plasmon resonance-and further evaluate the compounds in an NQO1 induction cell assay and in counter tests for nonspecific activities. Surprisingly, half of the compounds were inactive or deviated substantially from reported activities, while we confirm the cross-assay activities for others. Through this study, we have identified the most promising Keap1-Nrf2 inhibitors that can serve as pharmacological probes or starting points for developing CNS-active Keap1 inhibitors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据